Table 3.
Lipid-lowering effect of inclisiran. Modified from Ray, K.K et al. [115].
| Parameter | Inclisiran | Placebo | Placebo Adjusted | p Value |
|---|---|---|---|---|
| Total cholesterol | −24.7% | +0.3% | −25.1% | <0.0001 |
| LDL-C | −40.4% | +0.6% | −41.0% | <0.0001 |
| ApoB | −35.5% | −0.7% | −34.8% | <0.0001 |
| Non-HDL-C | −35.5% | −0.2% | −35.3% | <0.0001 |
| Triglycerides | −5.9% | 2.5% | −8.4% | =0.045 |
| Lipoprotein(a) | −12.1% | +16.8% | −28.9% | <0.0001 |
| HDL-C | +11% | +6.0% | +5.0% | =0.02 |
ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.